Consolidated Statement of Comprehensive Income Ono Pharmaceutical Co., Ltd. and Consolidated Subsidiaries

Profit for the period	Millions of yen				Thousands of US\$	
	Year ended March 31, 2017		Year ended March 31, 2018		Year ended March 31, 2018	
	¥	56,036	¥	50,397	\$	475,445
Other comprehensive income:						
Items that will not be reclassified to profit or loss:						
Net gain (loss) on financial assets measured at fair value through other comprehensive income		10,979		17,797		167,901
Remeasurement of defined benefit plans		1,165		(478)		(4,514)
Share of net gain (loss) on financial assets measured at fair value through other comprehensive income of investments in associates		0		2		22
Total of items that will not be reclassified to profit or loss		12,144		17,321		163,408
Items that may be reclassified subsequently to profit or le	oss:					
Exchange differences on translation of foreign operations		(96)		(112)		(1,054)
Total of items that may be reclassified subsequently to profit or loss		(96)		(112)		(1,054)
Total other comprehensive income (loss)		12,048		17,210		162,355
Total comprehensive income for the period		68,083		67,607		637,800
Comprehensive income for the period attributable to	:					
Owners of the parent company		67,841		67,477		636,571
Non-controlling interests		242		130		1,228
Total comprehensive income for the period		68,083		67,607		637,800